* Orthofix Medical Inc OFIX.OQ OFIX.O is expected
to show a
rise in quarterly revenue when it reports results on August 8.
* The Lewisville Texas-based company is expected to report
a
57.2% increase in revenue to $185.633 million from $118.07
million a year ago, according to the mean estimate from 3
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Orthofix Medical
Inc is
for a loss of 47 cents per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," 1 "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Orthofix
Medical
Inc is $29, above its last closing price of $18.44.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 -0.52 -0.51 -0.10 Beat 80.4
Dec. 31 2023 0.34 0.10 0.19 Beat 83.9
Sep. 30 2022 0.13 0.12 0.13 Beat 11.4
Jun. 30 2022 0.10 0.10 0.08 Missed -20
Mar. 0.10 0.09 -0.10 Missed -215.4
31 2022
Dec. 31 2021 0.13 0.13 0.27 Beat 107.7
Sep. 30 2021 0.11 0.11 0.10 Missed -10.4
Jun. 30 2021 0.13 0.11 0.32 Beat 190.9
This summary was machine generated August 5 at 02:11 GMT. All
figures in US dollars unless otherwise stated